In our current study, we have shown that the combination of Rap with Dex effectively inhibited the mTOR/p70S6K/glycolysis signaling pathway and induced autophagy, which led to the restoration of GC sensitivity in Rap- and Dex-resistant Raji cells in vitro and in vivo. Therefore, the combination of an mTOR inhibitor with Dex is a promising therapeutic approach for GC-resistant Burkitt lymphoma. Here, LRPAP1 is linked to Burkitt lymphoma.